Content

Welcome to the CJU website » LOG IN

Details

Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence
Department of Surgery, University of Toronto, Sunnybrook Health Science Center,
Sep 1996 (Vol. 3, Issue 3, Pages( 246 - 250)

Abstract

Text-Size + 

  • The conflicting data surrounding the benefit of total androgen blockade compared to monotherapy for metastatic prostate cancer is reviewed. The recent Lancet meta-analysis is critically appraised. A sensitivity analysis of the studies is presented.

Current Issue

October 2019, Vol.26 No.5
canadian journal of urology